Ibsrela FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 8, 2019.
Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
Development timeline for Ibsrela
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.